The Viral Vaccines Market is expected to register a CAGR of 8.7% from 2025 to 2031, with a market size expanding from US$ XX million in 2024 to US$ XX Million by 2031.
The Viral Vaccines Market report covers analysis by Type of Vaccine (Preventive, and Therapeutic); Route of Administration (Oral, and Injectable); Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Research Institutes), and Geography (North America, Europe, Asia Pacific, and South and Central America). The global analysis is further broken-down at regional level and major countries. The report Offers the Value in US$ for the above analysis and segments.
Purpose of the ReportThe report Viral Vaccines Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Viral Vaccines Market Segmentation
Type of Vaccine- Preventive
- Therapeutic
- Oral
- Injectable
- Hospital Pharmacies
- Online Pharmacies
- Research Institutes
Strategic Insights
Viral Vaccines Market Growth Drivers- Immunization-Related Programs by the Government: Vaccination is advocated by national and international agencies. Initiatives such as the Expanded Programme on Immunization (EPI), WHO, and global partnerships, such as Gavi and the Vaccine Alliance, seek to make vaccines available, particularly in developing countries. Subsidies, campaigns to raise public awareness, and immunization legislation policies have all led to increased vaccination uptake. In several countries, vaccines are provided free or at subsidized rates, enhancing their acceptance and use.
- Advances in Technology: In addition to more conventional means of vaccine preparation (live attenuated/inactivated viral vaccines), mRNA and DNA-based vaccine development technologies are being adopted and, in some instances, are replacing traditional approaches. These newer technologies greatly accelerate the development period and allow for precise targeting of viral antigens to optimize efficacy and safety. For example, the beauty of mRNA technology in COVID-19 vaccines is its capacity to address different variants or different viruses, thus, contributing to a versatile arsenal against viral threats. Recombinant vector vaccines, the kind used in the Ebola vaccine, also show good promise for getting a strong immune response.
- Rising Awareness and Investment in Healthcare: Public health-related campaigns, media interactions, and the realities of recent pandemics have been instrumental in raising public consciousness about the advantages of vaccination. The general population now knows vaccines can prevent not just personal illness but even large-scale outbreaks. With increased investments in healthcare infrastructure, vaccination programs are increasingly getting government funds, improving their distribution systems, cold chain logistics, and training of health professionals. Private investments have witnessed a new surge in biotech companies to spur R&D and commercialization of new vaccines.
- Shift Toward mRNA and DNA-Based Vaccines: The move toward mRNA and DNA-based vaccines has been spurred on by the remarkable efficacy of mRNA vaccines during the COVID-19 pandemic. The horizon is now being opened for more research relating to their use against other viral diseases like influenza, Zika fever, and, perhaps, even HIV. The advantages of mRNA vaccines are various: shortened times for development, flexibility in changing to new virulent strains, and cheaper ability of production. The speed and efficacy demonstrated by companies such as Pfizer-BioNTech and Moderna have set a new standard for the development of vaccines consequently encouraging directions into DNA vaccines and other nucleic acid technology.
- Combination Vaccines: Combination vaccines are those that protect against various diseases in a single shot, thereby simplifying the immunization schedule and improving compliance. For example, the MMR vaccine prevents measles, mumps, and rubella with 1 shot, while DTP is coverage for diphtheria, tetanus, and pertussis. Newly studied vaccines combine COVID-19 and influenza or hepatitis A and B. These innovations minimize the number of healthcare visits, reduce logistical expenses, and improve vaccination rates, especially in pediatric care.
- Personalized Vaccines: The personalized medicine paradigm is now extended to vaccine development. Therapeutic vaccines to combat chronic viral infection and some cancers are being designed with the intention of individualization by having the vaccine prepared according to the individual's genetic makeup or some characteristics of the virus present in the individual. For example, in therapeutic vaccines for HIV, stimulation of an immune response that might control the virus is aimed for. In a similar vein, oncolytic viral therapy offers yet another avenue to cancer treatment, in which the therapeutic agent, a virus, is directed specifically toward cancer cells for killing while sparing normal cells.
- Investing in Research and Development on Novel Viruses: The trend of new viral threats such as Zika, Ebola, and Nipah has indicated that investments in continuous research and development for vaccines against such emerging and re-emerging infectious diseases must be entered into. These, coupled with climate change, increased human-animal interactions, and deforestation, contribute to the creation of conditions for zoonotic disease spread for developing new vaccines, while, governments and private organizations are allocating funds to enabling rapid vaccine development platforms for pandemic preparedness against future outbreaks.
- Strategic Collaborations and Partnerships: They innovate in the vaccine market by forming collaborations among pharmaceutical companies, biotech startups, government agencies, and academic institutions. Examples like Pfizer-BioNTech and Oxford-AstraZeneca during the COVID-19 pandemic have proven how collating resources and expertise could speed up the whole process of vaccine development. They are also part of public-private partnerships that ensure equitable distribution of vaccines in low-income countries. Initiatives like COVAX give hope for making fair access to the COVID-19 vaccines available globally.
- Integrating Digital Health: Digital technology completely changes the way vaccines are developed and supplied as well as the way they are administered. Artificial intelligence (AI) and machine learning predict viral outbreaks, define targets for vaccines, and optimize designs for clinical trial conduct. Blockchain can increase vaccine supply chain transparency and traceability, while mobile health (mHealth) apps can track schedules for vaccinations, monitor side effects, and help educate patients in these areas. These tools ultimately improve efficiencies, reduce costs, and increase patient engagement in their prevention efforts.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Viral Vaccines Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Viral Vaccines Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The major factors driving the Viral Vaccines Market are Immunization-Related Programs by the Government, Advances in Technology, and Rising Awareness and Investment in Healthcare
The key future trends of the market are Shift Toward mRNA and DNA-Based Vaccines, Combination Vaccines, and Personalized Vaccines
The leading players operating in the Viral Vaccines Market include GlaxoSmithKline Plc, Sanofi, Novartis, Inc., MedImmune, LLC, Protein Sciences Corporation, Serum Institute of India Ltd., Seqirus, Emergent Product Development Gaithersburg, Inc., Merck & Co., Inc., Bharat Biotech.
The report can be delivered in PDF/PPT format; we can also share excel dataset based on the request.
Some of the customization options available based on the request are an additional 3–5 company profiles and country-specific analysis of 3–5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation, as our team would review the same and check the feasibility.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Viral Vaccines Market - By Type of Vaccine
1.3.2 Viral Vaccines Market - By Route of Administration
1.3.3 Viral Vaccines Market - By Distribution Channel
1.3.4 Viral Vaccines Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. VIRAL VACCINES MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. VIRAL VACCINES MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. VIRAL VACCINES MARKET - GLOBAL MARKET ANALYSIS
6.1. VIRAL VACCINES - GLOBAL MARKET OVERVIEW
6.2. VIRAL VACCINES - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. VIRAL VACCINES MARKET - REVENUE AND FORECASTS TO 2028 - TYPE OF VACCINE
7.1. OVERVIEW
7.2. TYPE OF VACCINE MARKET FORECASTS AND ANALYSIS
7.3. PREVENTIVE
7.3.1. Overview
7.3.2. Preventive Market Forecast and Analysis
7.4. THERAPEUTIC
7.4.1. Overview
7.4.2. Therapeutic Market Forecast and Analysis
8. VIRAL VACCINES MARKET - REVENUE AND FORECASTS TO 2028 - ROUTE OF ADMINISTRATION
8.1. OVERVIEW
8.2. ROUTE OF ADMINISTRATION MARKET FORECASTS AND ANALYSIS
8.3. ORAL
8.3.1. Overview
8.3.2. Oral Market Forecast and Analysis
8.4. INJECTABLE
8.4.1. Overview
8.4.2. Injectable Market Forecast and Analysis
9. VIRAL VACCINES MARKET - REVENUE AND FORECASTS TO 2028 - DISTRIBUTION CHANNEL
9.1. OVERVIEW
9.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
9.3. HOSPITAL PHARMACIES
9.3.1. Overview
9.3.2. Hospital Pharmacies Market Forecast and Analysis
9.4. ONLINE PHARMACIES
9.4.1. Overview
9.4.2. Online Pharmacies Market Forecast and Analysis
9.5. RESEARCH INSTITUTES
9.5.1. Overview
9.5.2. Research Institutes Market Forecast and Analysis
10. VIRAL VACCINES MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Viral Vaccines Market Overview
10.1.2 North America Viral Vaccines Market Forecasts and Analysis
10.1.3 North America Viral Vaccines Market Forecasts and Analysis - By Type of Vaccine
10.1.4 North America Viral Vaccines Market Forecasts and Analysis - By Route of Administration
10.1.5 North America Viral Vaccines Market Forecasts and Analysis - By Distribution Channel
10.1.6 North America Viral Vaccines Market Forecasts and Analysis - By Countries
10.1.6.1 United States Viral Vaccines Market
10.1.6.1.1 United States Viral Vaccines Market by Type of Vaccine
10.1.6.1.2 United States Viral Vaccines Market by Route of Administration
10.1.6.1.3 United States Viral Vaccines Market by Distribution Channel
10.1.6.2 Canada Viral Vaccines Market
10.1.6.2.1 Canada Viral Vaccines Market by Type of Vaccine
10.1.6.2.2 Canada Viral Vaccines Market by Route of Administration
10.1.6.2.3 Canada Viral Vaccines Market by Distribution Channel
10.1.6.3 Mexico Viral Vaccines Market
10.1.6.3.1 Mexico Viral Vaccines Market by Type of Vaccine
10.1.6.3.2 Mexico Viral Vaccines Market by Route of Administration
10.1.6.3.3 Mexico Viral Vaccines Market by Distribution Channel
10.2. EUROPE
10.2.1 Europe Viral Vaccines Market Overview
10.2.2 Europe Viral Vaccines Market Forecasts and Analysis
10.2.3 Europe Viral Vaccines Market Forecasts and Analysis - By Type of Vaccine
10.2.4 Europe Viral Vaccines Market Forecasts and Analysis - By Route of Administration
10.2.5 Europe Viral Vaccines Market Forecasts and Analysis - By Distribution Channel
10.2.6 Europe Viral Vaccines Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Viral Vaccines Market
10.2.6.1.1 Germany Viral Vaccines Market by Type of Vaccine
10.2.6.1.2 Germany Viral Vaccines Market by Route of Administration
10.2.6.1.3 Germany Viral Vaccines Market by Distribution Channel
10.2.6.2 France Viral Vaccines Market
10.2.6.2.1 France Viral Vaccines Market by Type of Vaccine
10.2.6.2.2 France Viral Vaccines Market by Route of Administration
10.2.6.2.3 France Viral Vaccines Market by Distribution Channel
10.2.6.3 Italy Viral Vaccines Market
10.2.6.3.1 Italy Viral Vaccines Market by Type of Vaccine
10.2.6.3.2 Italy Viral Vaccines Market by Route of Administration
10.2.6.3.3 Italy Viral Vaccines Market by Distribution Channel
10.2.6.4 Spain Viral Vaccines Market
10.2.6.4.1 Spain Viral Vaccines Market by Type of Vaccine
10.2.6.4.2 Spain Viral Vaccines Market by Route of Administration
10.2.6.4.3 Spain Viral Vaccines Market by Distribution Channel
10.2.6.5 United Kingdom Viral Vaccines Market
10.2.6.5.1 United Kingdom Viral Vaccines Market by Type of Vaccine
10.2.6.5.2 United Kingdom Viral Vaccines Market by Route of Administration
10.2.6.5.3 United Kingdom Viral Vaccines Market by Distribution Channel
10.2.6.6 Russia Viral Vaccines Market
10.2.6.6.1 Russia Viral Vaccines Market by Type of Vaccine
10.2.6.6.2 Russia Viral Vaccines Market by Route of Administration
10.2.6.6.3 Russia Viral Vaccines Market by Distribution Channel
10.2.6.7 Rest of Europe Viral Vaccines Market
10.2.6.7.1 Rest of Europe Viral Vaccines Market by Type of Vaccine
10.2.6.7.2 Rest of Europe Viral Vaccines Market by Route of Administration
10.2.6.7.3 Rest of Europe Viral Vaccines Market by Distribution Channel
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Viral Vaccines Market Overview
10.3.2 Asia-Pacific Viral Vaccines Market Forecasts and Analysis
10.3.3 Asia-Pacific Viral Vaccines Market Forecasts and Analysis - By Type of Vaccine
10.3.4 Asia-Pacific Viral Vaccines Market Forecasts and Analysis - By Route of Administration
10.3.5 Asia-Pacific Viral Vaccines Market Forecasts and Analysis - By Distribution Channel
10.3.6 Asia-Pacific Viral Vaccines Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Viral Vaccines Market
10.3.6.1.1 Australia Viral Vaccines Market by Type of Vaccine
10.3.6.1.2 Australia Viral Vaccines Market by Route of Administration
10.3.6.1.3 Australia Viral Vaccines Market by Distribution Channel
10.3.6.2 China Viral Vaccines Market
10.3.6.2.1 China Viral Vaccines Market by Type of Vaccine
10.3.6.2.2 China Viral Vaccines Market by Route of Administration
10.3.6.2.3 China Viral Vaccines Market by Distribution Channel
10.3.6.3 India Viral Vaccines Market
10.3.6.3.1 India Viral Vaccines Market by Type of Vaccine
10.3.6.3.2 India Viral Vaccines Market by Route of Administration
10.3.6.3.3 India Viral Vaccines Market by Distribution Channel
10.3.6.4 Japan Viral Vaccines Market
10.3.6.4.1 Japan Viral Vaccines Market by Type of Vaccine
10.3.6.4.2 Japan Viral Vaccines Market by Route of Administration
10.3.6.4.3 Japan Viral Vaccines Market by Distribution Channel
10.3.6.5 South Korea Viral Vaccines Market
10.3.6.5.1 South Korea Viral Vaccines Market by Type of Vaccine
10.3.6.5.2 South Korea Viral Vaccines Market by Route of Administration
10.3.6.5.3 South Korea Viral Vaccines Market by Distribution Channel
10.3.6.6 Rest of SouthEast Asia Viral Vaccines Market
10.3.6.6.1 Rest of SouthEast Asia Viral Vaccines Market by Type of Vaccine
10.3.6.6.2 Rest of SouthEast Asia Viral Vaccines Market by Route of Administration
10.3.6.6.3 Rest of SouthEast Asia Viral Vaccines Market by Distribution Channel
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Viral Vaccines Market Overview
10.4.2 Middle East and Africa Viral Vaccines Market Forecasts and Analysis
10.4.3 Middle East and Africa Viral Vaccines Market Forecasts and Analysis - By Type of Vaccine
10.4.4 Middle East and Africa Viral Vaccines Market Forecasts and Analysis - By Route of Administration
10.4.5 Middle East and Africa Viral Vaccines Market Forecasts and Analysis - By Distribution Channel
10.4.6 Middle East and Africa Viral Vaccines Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Viral Vaccines Market
10.4.6.1.1 South Africa Viral Vaccines Market by Type of Vaccine
10.4.6.1.2 South Africa Viral Vaccines Market by Route of Administration
10.4.6.1.3 South Africa Viral Vaccines Market by Distribution Channel
10.4.6.2 Saudi Arabia Viral Vaccines Market
10.4.6.2.1 Saudi Arabia Viral Vaccines Market by Type of Vaccine
10.4.6.2.2 Saudi Arabia Viral Vaccines Market by Route of Administration
10.4.6.2.3 Saudi Arabia Viral Vaccines Market by Distribution Channel
10.4.6.3 U.A.E Viral Vaccines Market
10.4.6.3.1 U.A.E Viral Vaccines Market by Type of Vaccine
10.4.6.3.2 U.A.E Viral Vaccines Market by Route of Administration
10.4.6.3.3 U.A.E Viral Vaccines Market by Distribution Channel
10.4.6.4 Rest of Middle East and Africa Viral Vaccines Market
10.4.6.4.1 Rest of Middle East and Africa Viral Vaccines Market by Type of Vaccine
10.4.6.4.2 Rest of Middle East and Africa Viral Vaccines Market by Route of Administration
10.4.6.4.3 Rest of Middle East and Africa Viral Vaccines Market by Distribution Channel
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Viral Vaccines Market Overview
10.5.2 South and Central America Viral Vaccines Market Forecasts and Analysis
10.5.3 South and Central America Viral Vaccines Market Forecasts and Analysis - By Type of Vaccine
10.5.4 South and Central America Viral Vaccines Market Forecasts and Analysis - By Route of Administration
10.5.5 South and Central America Viral Vaccines Market Forecasts and Analysis - By Distribution Channel
10.5.6 South and Central America Viral Vaccines Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Viral Vaccines Market
10.5.6.1.1 Brazil Viral Vaccines Market by Type of Vaccine
10.5.6.1.2 Brazil Viral Vaccines Market by Route of Administration
10.5.6.1.3 Brazil Viral Vaccines Market by Distribution Channel
10.5.6.2 Argentina Viral Vaccines Market
10.5.6.2.1 Argentina Viral Vaccines Market by Type of Vaccine
10.5.6.2.2 Argentina Viral Vaccines Market by Route of Administration
10.5.6.2.3 Argentina Viral Vaccines Market by Distribution Channel
10.5.6.3 Rest of South and Central America Viral Vaccines Market
10.5.6.3.1 Rest of South and Central America Viral Vaccines Market by Type of Vaccine
10.5.6.3.2 Rest of South and Central America Viral Vaccines Market by Route of Administration
10.5.6.3.3 Rest of South and Central America Viral Vaccines Market by Distribution Channel
11. IMPACT OF COVID-19 PANDEMIC ON GLOBAL VIRAL VACCINES MARKET
11.1 North America
11.2 Europe
11.3 Asia-Pacific
11.4 Middle East and Africa
11.5 South and Central America
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. VIRAL VACCINES MARKET, KEY COMPANY PROFILES
13.1. GLAXOSMITHKLINE PLC
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. SANOFI
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. NOVARTIS, INC.
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. MEDIMMUNE, LLC
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Products and Services
13.4.4. Financial Overview
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. PROTEIN SCIENCES CORPORATION
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Products and Services
13.5.4. Financial Overview
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. SERUM INSTITUTE OF INDIA LTD.
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Products and Services
13.6.4. Financial Overview
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. SEQIRUS
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Products and Services
13.7.4. Financial Overview
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG, INC.
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Products and Services
13.8.4. Financial Overview
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. MERCK & CO., INC.
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Products and Services
13.9.4. Financial Overview
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. BHARAT BIOTECH
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Products and Services
13.10.4. Financial Overview
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS
1. GlaxoSmithKline Plc
2. Sanofi
3. Novartis, Inc.
4. MedImmune, LLC
5. Protein Sciences Corporation
6. Serum Institute of India Ltd.
7. Seqirus
8. Emergent Product Development Gaithersburg, Inc.
9. Merck & Co., Inc.
10. Bharat Biotech
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For